Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index; 6 of the 55 sources its claims cite were checked for support.
Abstract
Orforglipron (LY3502970) is a novel, orally available, nonpeptide glucagon-like peptide-1 receptor agonist (GLP-1 RA) designed to replicate the efficacy of injectable GLP-1 RAs for glycemic control and weight reduction while improving convenience and adherence. Preclinical studies have demonstrated potent receptor engagement, favorable pharmacokinetics, and central nervous system activity. Phase 1–3 clinical trials have shown significant reductions in glycated hemoglobin (HbA1c), fasting and postprandial glucose, body weight, and cardiovascular risk biomarkers, with an acceptable safety profile. This comprehensive review integrates pharmacological, clinical, and mechanistic evidence, critically evaluates the data, identifies knowledge gaps, and outlines future directions for orforglipron in the treatment of type 2 diabetes and obesity.
Overview
CoChat Summary
TL;DR
Orforglipron is an oral, nonpeptide, allosteric GLP-1 receptor agonist that produces clinically meaningful HbA1c and weight reductions in type 2 diabetes and obesity, with a safety profile dominated by dose-dependent gastrointestinal events. This comprehensive review integrates preclinical, Phase 1–3, mechanistic, and meta-analytic evidence while highlighting unresolved questions about long-term outcomes, comparative effectiveness, and understudied populations.
Key findings
- Orforglipron is orally bioavailable (~30–40%), reaches peak plasma concentrations within 2–4 h, and supports once-daily dosing; food intake has minimal impact on exposure.
- In Phase 2 T2D trials, once-daily orforglipron produced dose-dependent HbA1c reductions exceeding 1.5 percentage points at 26 weeks and mean body weight reductions of 7–10% at 26 weeks.
- In ACHIEVE-1, early T2D patients had mean absolute HbA1c reductions of ~1.4–1.6% over 40 weeks without significant hypoglycemia; in ATTAIN, over 72 weeks, the highest dose yielded mean weight loss of 12–15% in non-diabetic participants and 10–12% in T2D populations.
- Meta-analyses cited in the review report pooled weight reductions of 9–12% versus placebo at 26–72 weeks and weighted mean HbA1c reductions of 1.3–1.6% versus placebo; gastrointestinal adverse events were the most common, while hypoglycemia was rare and no pancreatitis, retinal detachment, or ischemic optic neuropathy signals were observed.
Methods
- Design: comprehensive narrative review integrating preclinical pharmacology, Phase 1–3 clinical trials, mechanistic substudies, and published meta-analyses; no new primary data are reported.
- Data/sample: healthy volunteers, participants with T2D, participants with obesity with or without diabetes, Japanese participants with T2D, and trial populations from ACHIEVE-1 and ATTAIN-1/ATTAIN-2.
- Main analysis: qualitative synthesis of pharmacokinetic, pharmacodynamic, glycemic, weight-loss, safety, cardiovascular biomarker, hepatic, and renal data, with summary tables and cross-trial comparisons.
Limitations
- Stated in the paper: most trials lasted only ~26–72 weeks, limiting assessment of long-term durability, late-emerging adverse events, and sustained cardiometabolic benefit; elderly patients, adolescents, individuals with severe obesity, and those with advanced renal or hepatic impairment were excluded or minimally represented; real-world effectiveness data are lacking; direct head-to-head comparisons and hard cardiovascular/renal outcome trials are absent.
- Stated in the paper: mechanistic gaps remain, including the relative contributions of weight-dependent versus weight-independent glycemic effects, central appetite pathways, β-cell preservation, and the molecular basis of nonpeptide allosteric activation.
- Evident from the text: as a narrative review, conclusions rely on cross-trial comparisons and surrogate biomarkers rather than primary comparative or long-term outcome data; no systematic search or formal quality appraisal is described.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
1 Valid · 2 Not valid · 27 Not checked · 25 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In adults with T2D, participants receiving the higher dose regimens achieved mean body weight reductions of 7–10% at 26 weeks, with progressive weight loss observed over the study period [29].”
§ Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes > 4. Weight Loss and Obesity Outcomes > 4.1. Phase 2 Evidence
What the sources say
- Disputedcites [29] Pratt E. Ma X. Liu R. Robins D. Coskun T. Sloop K.W. Haupt A. Benson C. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes Diabetes Obes. Metab. 2023 25 2642 2649 10.1111/dom.15150 37264711 sourceExperimental — accuracy not yet measured
Our copy is a Phase 1b study of only 12 weeks' duration: the Abstract reports body weight change of -0.24 to -5.8 kg across orforglipron doses versus 0.5 kg with placebo at Week 12, and the Discussion/Figure 3 give LSM differences of approximately -4 to -6 kg versus placebo at Week 12 — no percentage-based weight loss and no 26-week timepoint anywhere. Decisively, the Discussion states that 'two Phase 2 trials are currently ongoing in patients with T2D (NCT05048719) and in patients with obesity (NCT05051579)', i.e. this paper reports no Phase 2 results at all, and it explicitly notes its own small sample size and short exposure as limitations requiring larger, longer trials. Thus the attributed finding (7-10% mean body weight reduction at 26 weeks in Phase 2, higher dose regimens) is contrary to what this source says; the only 'progressive weight loss' it supports is over Day 7 to Week 12. (LLM, conf=0.78)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
None of the sources cited for this claim have been checked yet.
In the paper
“Notably, a substantial proportion of participants achieved ≥10% weight loss, a threshold associated with meaningful metabolic improvements and cardiovascular risk reduction.”
§ Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes > 4. Weight Loss and Obesity Outcomes > 4.2. ATTAIN Trials
What the sources say
- Not checked yetcites [25] Wharton S. Blevins T. Connery L. Rosenstock J. Raha S. Liu R. Ma X. Mather K.J. Haupt A. Robins D. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity N. Engl. J. Med. 2023 389 877 888 10.1056/NEJMoa2302392 37351564 source
- Not checked yetcites [30] Horn D.B. Ryan D.H. Kis S.G. Alves B. Mu Y. Kim S.G. Aberle J. Bain S.C. Allen S. Sarker E. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): A phase 3, double-blind, randomised, multicentre, placebo-controlled trial Lancet 2026 406 2927 2944 10.1016/S0140-6736(25)02165-8 41275875 source
- Not checked yetcites [46] Wharton S. Aronne L.J. Stefanski A. Alfaris N.F. Ciudin A. Yokote K. Halpern B. Shukla A.P. Zhou C. Macpherson L. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment N. Engl. J. Med. 2025 393 1796 1806 10.1056/NEJMoa2511774 40960239 source
- Could not verifycites [47] Wharton S. Rosenstock J. Konige M. Lin Y. Duffin K. Wilson J. Banerjee H. Pirro V. Kazda C. Mather K. Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes Cardiovasc. Diabetol. 2025 24 240 10.1186/s12933-025-02781-x 40481478 PMC12142847 sourceExperimental — accuracy not yet measured
The Introduction reports average weight loss in two Phase 2 orforglipron studies, and Methods identifies those studies by trial registration number (pages unavailable). Neither passage identifies an ATTAIN trial or reports the proportion of participants who lost at least 10% of their weight; searches for ATTAIN and the 10% responder threshold found no such passage in our copy. (LLM, conf=0.78)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Meta-analyses of randomized controlled trials corroborate these findings, demonstrating pooled weight reductions of 9–12% relative to placebo at 26–72 weeks [49,50].”
§ Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes > 4. Weight Loss and Obesity Outcomes > 4.3. Comparative Context
What the sources say
- Partly supportedcites [49] Dutta D. Nagendra L. Anne B. Kumar M. Sharma M. Kamrul-Hasan A.B.M. Orforglipron, a novel non-peptide oral daily glucagon-like peptide-1 receptor agonist as an anti-obesity medicine: A systematic review and meta-analysis Obes. Sci. Pract. 2024 10 e743 10.1002/osp4.743 38414573 PMC10896246 sourceExperimental — accuracy not yet measured
Dutta et al. (2024) is indeed a systematic review and meta-analysis of orforglipron RCTs, and it does report placebo-corrected percent weight reductions, so the general point holds. But the magnitudes and time frame are not what the paper shows: its pooled (meta-analytic) reductions vs placebo at 26 weeks are MD −5.48% (12 mg), −8.51% (24 mg), −8.84% (36 mg) and −8.24% (45 mg) (RESULTS, Effect on body weight and body mass index), i.e. ~5.5–8.8%, not 9–12%; the only 9–12%-range figures are the 7.1%–12.3% placebo-corrected changes reported narratively by one included trial (Wharton 2023) at week 36, not a pooled estimate. The 72-week endpoint is unsupported: the Abstract (Results) states data from three RCTs in 774 people with follow-up duration of up to 36 weeks, and no passage in our copy reports 72-week outcomes. (LLM, conf=0.80)
- Partly supportedcites [50] Lutkemeyer C. Pasqualotto E. Ferreira R.O.M. Chavez M.P. Petris I. Jr. Dos Santos H.V. Wille J.M. Hohl A. Ronsoni M.F. van de Sande-Lee S. Effects of once-daily oral orforglipron on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials Arch. Endocrinol. Metab. 2024 68 e230469 10.20945/2359-4292-2023-0469 39420937 PMC11460968 sourceExperimental — accuracy not yet measured
Our copy is indeed a systematic review/meta-analysis of four RCTs (815 patients) reporting greater weight reduction with orforglipron versus placebo, but its pooled percentage figure is WMD -8.01% (95% CI -12.51 to -3.52%; two trials, 605 participants) and its absolute figure -6.14 kg (four trials, 733 participants) — below the claimed 9–12% point range. The duration qualifier is also unsupported: Table 1 (Study selection and characteristics) lists follow-ups of 4, 12 and 26 weeks only, and the Discussion states the included phase 1 and 2 RCTs 'had short follow-ups' with no plateau reached, so nothing here covers 26–72 weeks. Thus the direction and existence of a pooled placebo-relative effect are supported, while the 9–12% magnitude and the up-to-72-week timeframe attributed to this source are not. (LLM, conf=0.82)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Importantly, the absence of clinically relevant hepatic or renal toxicity suggests that no dose adjustment is required in patients with mild to moderate hepatic or renal dysfunction, a practical advantage in routine clinical practice [34].”
§ Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes > 5. Safety, Tolerability, and Cardiovascular Biomarkers > 5.3. Hepatic and Renal Safety
What the sources say
- Could not verifycites [34] Gogineni P. Melson E. Papamargaritis D. Davies M. Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: Where are we now? Expert Opin. Pharmacother. 2024 25 801 818 10.1080/14656566.2024.2356254 38753454 PMC11195668 sourceExperimental — accuracy not yet measured
Our copy's Orforglipron section and Table 3 report only HbA1c/weight/BP efficacy and a gastrointestinal-predominant AE profile (12-19% discontinuation), with no statement about hepatic or renal toxicity and no statement about dose adjustment in mild to moderate hepatic or renal impairment (searched: 'dose adjustment', 'hepatic/renal impairment', 'orforglipron liver kidney'). The nearest dosing statement — that orforglipron 'has minimal dosing requirements (i.e it does not require to be taken on an empty stomach)' (Orforglipron, p. n/a) and 'less burdensome administration' in 'The future of oral GLP-1 RAs' — concerns food/water restrictions, not organ dysfunction, so it does not carry the attributed point. The only hepatic-toxicity content in our copy is about a different molecule, lotiglipron ('elevated transaminases and concerns regarding potential liver toxicity', Other oral GLP-1 RAs not progressed to phase 3 trials), which neither supports nor contradicts the claim. (LLM, conf=0.68)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
In the paper
“Improvements were consistent across baseline HbA1c, BMI, sex, and age subgroups, indicating broad applicability.”
§ Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes > 3. Glycemic Efficacy > 3.3. Phase 3 Evidence
What the sources say
- Not checked yetcites [27] Rosenstock J. Hsia S. Nevarez Ruiz L. Eyde S. Cox D. Wu W.S. Liu R. Li J. Fernandez Lando L. Denning M. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes N. Engl. J. Med. 2025 393 1065 1076 10.1056/NEJMoa2505669 40544435 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
27 more claims
Create a free account to see all 55 claims and to verify the 49 references still open.
- It may state two separate claims as one. 22
- The quote only partly states this claim. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Recently approved or emerging daily oral small-molecule GLP-1 agonists, such as orforglipron, may improve access and reduce injection burden [88].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [88]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes > 5. Safety, Tolerability, and Cardiovascular Biomarkers > 5.3. Hepatic and Renal Safety
“Detailed disposition analyses demonstrate that the compound undergoes limited hepatic metabolism and does not rely heavily on cytochrome P450–mediated pathways”
§ Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes > 5. Safety, Tolerability, and Cardiovascular Biomarkers > 5.3. Hepatic and Renal Safety
“Indeed, orforglipron is eliminated predominantly through hepatic metabolism, with Phase I oxidative biotransformation as the principal clearance mechanism. CYP-mediated metabolism (primarily involving CYP3A) is responsible for most systemic clearance”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes > 4. Weight Loss and Obesity Outcomes > 4.1. Phase 2 Evidence
“In adults with T2D, participants receiving the higher dose regimens achieved mean body weight reductions of 7–10% at 26 weeks, with progressive weight loss observed over the study period [29].”
§ Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes > References
“29. Pratt E. Ma X. Liu R. Robins D. Coskun T. Sloop K.W. Haupt A. Benson C. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes”
Citations
Cites
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments
Ruze, R., Liu, T., Zou, X., Song, J., Chen, Y., Xu, R., Yin, X., & Xu, Q. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1161521 · Cited by 799
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Wharton, S., Blevins, T., Connery, L., Rosenstock, J., Raha, S., Liu, R., Ma, X., Mather, K. J., Haupt, A., Robins, D., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2302392 · Cited by 478 · cited 2×
“Across both trials, orforglipron produced significant, sustained weight reductions over 72 weeks, with the highest dose yielding mean body weight loss of 12–15% in non-diabetic participants and 10–12% in T2D populations [25,30,46,47].”
Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist
Kawai, T., Sun, B., Yoshino, H., Feng, D., Suzuki, Y., Fukazawa, M., Nagao, S., Wainscott, D. B., Showalter, A. D., Droz, B. A., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2014879117 · Cited by 231 · cited 4×
“While structural studies have provided important insights into binding topology and receptor conformational changes [30,32,33,36–39], the extent to which different allosteric ligands induce biased signaling or differential receptor trafficking is not fully resolved.”
InfluentialOrforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
Wharton, S., Aronne, L. J., Stefanski, A., Alfaris, N. F., Ciudin, A., Yokote, K., Halpern, B., Shukla, A. P., Zhou, C., Macpherson, L., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2511774 · Cited by 189 · cited 1×
“Across both trials, orforglipron produced significant, sustained weight reductions over 72 weeks, with the highest dose yielding mean body weight loss of 12–15% in non-diabetic participants and 10–12% in T2D populations [25,30,46,47].”
Frias, J. P., Hsia, S., Eyde, S., Liu, R., Ma, X., Konig, M., Kazda, C., Mather, K. J., Haupt, A., Pratt, E., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01302-8 · Cited by 184 · cited 2×
“Once-daily orforglipron produced significant, dose-dependent reductions in HbA1c, with higher doses achieving reductions exceeding 1.5 percentage points at 26 weeks [26].”
InfluentialEfficacy of semaglutide in a subcutaneous and an oral formulation
Meier, J. J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645617 · Cited by 146 · cited 1×
“Oral formulations are highly desirable to improve patient acceptance and broaden therapeutic reach [24].”
Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists
Galli, M., Benenati, S., Laudani, C., Simeone, B., Sarto, G., Ortega‐Paz, L., Rocco, E., Bernardi, M., Spadafora, L., D’Amario, D., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.027 · Cited by 140
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
Rosenstock, J., Hsia, S., Nevarez Ruiz, L., Eyde, S., Cox, D., Wu, W.-S., Liu, R., Li, J., Fernández Landó, L., Denning, M., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2505669 · Cited by 132 · cited 4×
“These observations align with clinical data from larger efficacy trials, including ACHIEVE-1 and ATTAIN studies, in which renal function remained stable throughout treatment despite substantial weight loss and glycemic improvement [27,45,47,62,69].”
InfluentialKnop, F. K., Vilsbøll, T., Larsen, S., Højberg, P. V., Vølund, A., Madsbad, S., Holst, J. J., & Krarup, T. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00059.2006 · Cited by 120 · cited 1×
“…receptor agonists have been associated, in rare instances, with acute pancreatitis and ocular complications, including non-arteritic anterior ischemic optic neuropathy (NAION) and worsening diabetic retinopathy, as documented in post-marketing surveillance and regulatory safety reviews [51–60].”
Research works printed but not linked: 3
- Jagarlapudi S.P. Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes N. Engl. J. Med. 2025 393 2276 10.1056/NEJMc2515117 41337726 · DOI · Paper page
- Nagaoka T. Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes N. Engl. J. Med. 2025 393 2276 10.1056/NEJMc2515117 41337725 · DOI · Paper page
- Xie X. Xuan X. Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes N. Engl. J. Med. 2025 393 2276 2277 10.1056/NEJMc2515117 41337727 · DOI · Paper page
Cited by
Rabbani, S. A., Saini, M., El-Tanani, M. E.-T., Kumar, R., Matalka, I. I., El‐Tanani, Y., Sharma, S., & Rizzo, M. (2026) · Pharmaceuticals · doi:10.3390/ph19050732 · Cited by 5
Dziewierz, A., & Siudak, Z. (2026) · Nutrients · doi:10.3390/nu18111761 · Cited by 3
Zaman, W., & Amin, A. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2676109 · Cited by 2
“The FDA-approved labeling states that GLP-1 is a physiological regulator of appetite and caloric intake, and that orforglipron decreases food intake, reduces body weight, and delays gastric emptying [42].”
Li, Y., Glotfelty, E. J., Parekh, P., Batsaikhan, B., Luo, W., Jackson, S. N., Harvey, B. K., & Greig, N. H. (2026) · Cells · doi:10.3390/cells15141301 · Cited by 2
“Notably, the selected cell lines are of human origin, as orforglipron is known to selectively activate the human GLP-1R but to not bind or activate the wild-type mouse/rat GLP-1R [57,58].”
Daily Glucagon-like Peptide-1 Receptor Agonists in Type 1 Diabetes
Innes, R., Petrie, J. R., & Dejgaard, T. F. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.04.002
Lau, D. (2026) · Annals of Internal Medicine · doi:10.7326/annals-26-01781-jc
Castro-Gamboa, J. A., Mora-Jiménez, J., Arguedas‐Chacón, S., & Zavaleta‐Monestel, E. (2026) · Cureus · doi:10.7759/cureus.110178
Santulli, G. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-026-00321-4
Self-citationA Lineup for Next Anti-Obesity Medicines: Beyond Incretin-Based Pharmacotherapy
Lee, S. M., Song, H., & Kwon, Y. O.-S. (2026) · Pharmaceuticals · doi:10.3390/ph19071047
“In addition to the oral formulation of semaglutide, a non-peptide GLP-1 receptor agonist, orforglipron (Foundayo TM ), has been recently approved in the US for once-daily administration [24].”
Hadianawala, M., Mohanty, S. K., & Patil, S. N. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c02013
Potential nephroprotective mechanisms of orforglipron, an oral non-peptide GLP-1 receptor agonist
Ramadurgum, P., Shah, J., Shah, E., & PALMER, B. F. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1917800
Pucek, W. F., Hoffmann, K., Bryl, W., Kus, K., & Paczkowska, A. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1906959
“Phase 2 and phase 3 studies have demonstrated clinically meaningful reductions in body weight and HbA1c, while analyses in participants with T2DM or obesity without diabetes have reported improvements in systolic blood pressure, lipid measures, and other cardiovascular risk biomarkers (13 – 15).”
The role of GLP-1 and GIP receptor agonists in the treatment of diabetes and obesity
Roskoski, R. J. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108365 · Cited by 1
Medicinal and Crop Protection Chemistry: Breaking Barriers, Building Synergies
Cazzaniga, G., Fratello, G. L., Apostle, A. T., Orrù, R., Barber, D. M., & Gazzola, S. (2026) · ChemMedChem · doi:10.1002/cmdc.70441
“Orforglipron represents a first-in-class, nonpeptide, small-molecule GLP-1 receptor agonist designed for oral administration [88, 89].”
Oral small-molecule GLP-1 receptor agonists: a new Frontier in cardiometabolic medicine
Guo, J., & Chen, H. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1933018
“Injectable GLP-1 RAs require cold-chain storage, subcutaneous self-administration, and dose-escalation schedules that contribute to substantial real-world discontinuation within the first year of therapy (Kansakar et al., 2026).”
Shah, J., Ceron, E. L., Payan‐Schober, F., Hechanova, L. A., Clegg, D. J., & Palmer, B. F. (2026) · American Journal of Nephrology · doi:10.1159/ajn/ablag011
Orforglipron: An Oral GLP-1 Receptor Agonist for Obesity Treatment
Wietholter, J. P., & Terpening, C. M. (2026) · Annals of Pharmacotherapy · doi:10.1177/10600280261486055
GLP-1 Based Therapies for Obesity in Older Adults: Current Evidence and Emerging Treatments
Pendrey, A., Sierra, J. A. R., Alvarez, F. A., Muñoz, Y. M. F., & Sevilla‐Martir, J. (2026) · Global Journal of Obesity Diabetes and Metabolic Syndrome · doi:10.17352/gjodms.000071
Glucagon-Like Peptide-1 Receptor Agonist-Associated Hepatotoxicity
Palmer, M. (2026) · Clinical Therapeutics · doi:10.1016/j.clinthera.2026.09.002
Pînzariu, A. C., Șerban, I. L., Soroceanu, R. P., Vlăsceanu, V. I., Maxim, M., Miler, A. A., Leonte, S. M., Atodiresei, C., Moscalu, M., Manole, L. M., et al. (2026) · Cells · doi:10.3390/cells15191823
“…agonist orforglipron, whose adverse reactions are dominated by GI manifestations, while pharmacokinetic data from early clinical trials reveals the absence of acute hepatocellular or cholestatic toxicity, with no clinically significant increases in transaminases or total bilirubin reported [68].”
Identification of an Inhibitory Fraction from Cinnamomum cassia Against Digestive Lipases
Snini, S., Kamoun, J., Balogun, P., Fiore, M., Violot, S., Sellami, M., Ayciriex, S., Noiriel, A., Aloulou, A., & Abousalham, A. (2026) · Molecules · doi:10.3390/molecules31203737
Decoding the Safety Profile of GLP-1 Receptor Agonists: Facts, Myths, and Ongoing Controversies
Kounatidis, D. C., Vallianou, N. G., Kouveletsou, M., Kontrafouri, P., Stamatopoulos, V., Rebelos, E., Diakoumopoulou, E., & Dalamaga, Μ. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00770-z
Metadata
- Authors
- Kansakar, U., Jankauskas, S. S., Pande, S., Mone, P., Varzideh, F., & Santulli, G.
- Affiliations
- City University of New York (US)
- Casa di Cura “Clinica Montevergine”, 83013 Mercogliano, Italy
- Corresponding author
- Santulli, Gaetano
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2026-01-30
- Volume
- 27
- Issue
- 3
- Pages
- 1409
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC12898445
- OpenAlex
- W7126191026
- Cited by
- 22
- References
- 91
- Citations by year
- 2026: 22
- FWCI
- 23.39
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Funders
- National Institutes of Health (NIH): National Heart, Lung, and Blood Institute (R01-HL146691, R01-HL164772, R01-HL159062)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01-DK123259, R01-DK033823)
- American Heart Association (24IPA1268813)
- AHA (AHA-23POST1026190, AHA-21POST836407, 26POST1563063, AHAPOST22915561, AHAPOST241195524)
- NIH (T32-HL-172255)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- orforglipron, GLP-1 receptor agonists, oral GLP-1 receptor agonists, type 2 diabetes, obesity, glycemic control, weight loss, HbA1c, cardiovascular risk markers, pharmacokinetics, drug safety
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Administration, Oral, Animals, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Obesity, Oxadiazoles, Fluorine Compounds
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.